$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

INMD

InMode Ltd (INMD)

$16.07

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

01/14/2025: INMD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock

Historic Profit -23.25%

Avg. Invested days 25

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

2.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 1.23B USD	Price to earnings Ratio 8.78	1Y Target Price 20.83
Price to earnings Ratio 8.78	1Y Target Price 20.83
Volume (30-day avg) 869864	Beta 2.15	52 Weeks Range 14.87 - 26.80	Updated Date 01/14/2025
52 Weeks Range 14.87 - 26.80	Updated Date 01/14/2025
Dividends yield (FY) -	Basic EPS (TTM) 1.83

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin 36.26%

Operating Margin (TTM) 37.06%

Management Effectiveness

Return on Assets (TTM) 10.5%

Return on Equity (TTM) 21.05%

Valuation

Trailing PE 8.78	Forward PE 8.23	Enterprise Value 538127366	Price to Sales(TTM) 2.89
Enterprise Value 538127366	Price to Sales(TTM) 2.89
Enterprise Value to Revenue 1.27	Enterprise Value to EBITDA 3.94	Shares Outstanding 76249104	Shares Floating 69513895
Shares Outstanding 76249104	Shares Floating 69513895
Percent Insiders 10.76	Percent Institutions 63.28

AI Summary

InMode Ltd. Stock Analysis

Company Profile:

History and Background:

InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel. It develops and markets innovative, minimally-invasive medical technologies for aesthetic and surgical applications. The company's initial focus was on radiofrequency (RF) technologies, but it has expanded to include other energy-based platforms such as laser and diode. InMode currently operates in over 90 countries worldwide.

Core Business Areas:

InMode focuses on three primary business areas:

Minimally-invasive facial aesthetics: This includes technologies for skin tightening, wrinkle reduction, fat reduction, and body contouring.
Minimally-invasive surgical applications: This includes technologies for tissue ablation, hemostasis, and vessel sealing.
Women's health: This includes technologies for vaginal rejuvenation, urinary incontinence treatment, and hemorrhoid treatment.

Leadership Team:

Moshe Mizrahi: Chairman and CEO
Shakil Lakhani: Chief Operating Officer
Yair Malca: Chief Financial Officer
Dr. Michael D. Kreindel: Chief Medical Officer

Top Products and Market Share:

Top Products:

Forma: A platform for skin tightening and wrinkle reduction using RF technology.
Evolve: A platform for fat reduction and body contouring using RF and diode technologies.
Morpheus8: A platform for skin rejuvenation, tightening, and subdermal remodeling using RF technology.
EmbraceRF: A platform for vaginal rejuvenation and urinary incontinence treatment using RF technology.
Lumenis NuEra Tight: A platform for skin tightening and wrinkle reduction using laser technology.

Market Share:

InMode holds a significant market share in the minimally-invasive aesthetic medical device market. The company estimates its global market share for body contouring at approximately 30% and for facial aesthetics at approximately 10%.

Total Addressable Market:

The global aesthetic medical device market is estimated to be worth approximately $15 billion and is expected to grow at a CAGR of 9.2% through 2027.

Financial Performance:

Recent Financial Statements:

Revenue: $249.5 million in 2022, up 11% year-over-year.
Net Income: $62.4 million in 2022, up 21% year-over-year.
Profit Margin: 25% in 2022.
EPS: $1.69 in 2022, up 21% year-over-year.

Cash Flow and Balance Sheet:

InMode has a strong cash flow position with $235 million in cash and equivalents as of December 31, 2022. The company also has a healthy balance sheet with minimal debt.

Dividends and Shareholder Returns:

Dividend History:

InMode does not currently pay a dividend.

Shareholder Returns:

InMode's stock has returned over 100% in the past year and over 500% in the past three years.

Growth Trajectory:

Historical Growth:

InMode has experienced strong historical growth, with revenue increasing at a CAGR of over 30% from 2018 to 2022.

Future Growth:

The company expects continued strong growth in the coming years, driven by new product launches, international expansion, and increasing adoption of its minimally-invasive technologies.

Market Dynamics:

The aesthetic medical device market is driven by several factors, including the growing demand for non-surgical cosmetic procedures, the aging population, and increasing disposable income. InMode is well-positioned to benefit from these trends.

Competitors:

Key Competitors:

BTL Aesthetics (BTLA)
Cynosure (CYNO)
Lumenis (LMNS)
Solta Medical (SLTM)

Competitive Advantages:

InMode's competitive advantages include its innovative technologies, strong brand recognition, global distribution network, and recurring revenue model.

Potential Challenges and Opportunities:

Challenges:

Intense competition from established players.
Potential for technological advancements to render existing products obsolete.
Regulatory hurdles.

Opportunities:

International expansion.
New product launches.
Strategic partnerships.

Recent Acquisitions:

Mirabilis Medical (2022): This acquisition added RF technology for urinary incontinence treatment to InMode's portfolio.
BodyTite (2021): This acquisition expanded InMode's minimally-invasive body contouring offerings.
Evolve (2021): This acquisition added a new platform for fat reduction and body contouring using RF and diode technologies.

AI-Based Fundamental Rating:

Rating: 8/10

Justification:

InMode has strong fundamentals, including a growing top line, healthy profitability, and a solid balance sheet. The company also has a strong competitive position and significant growth potential. However, the stock is currently trading at a high valuation, which could pose a risk to investors.

Disclaimer:

This analysis is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Sources:

InMode Ltd. Investor Relations website
SEC filings
Industry reports

Note: This analysis is based on publicly available information as of November 15, 2023.

About NVIDIA Corporation

Exchange NASDAQ	Headquaters -
IPO Launch date 2019-08-08	CEO & Director Mr. Moshe Mizrahy
Sector Healthcare	Industry Medical Devices	Full time employees 581	Website https://www.inmodemd.com
Full time employees 581	Website https://www.inmodemd.com

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.